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ABSTRACT: Formal homologation of sp2-hybridized boronic
acids is achieved via cross-coupling of boronic acids with
conjunctive haloaryl BMIDA components in the presence of a
suitably balanced basic phase. The utility of this approach to
provide a platform for diversity-oriented synthesis in discovery
medicinal chemistry is demonstrated in the context of the
synthesis of a series of analogues of a BET bromodomain
inhibitor.
Boronic acids are among the most versatile of functionalgroups, capable of a diverse array of chemical reactions.1
Their superior reactivity enables many transformations that
other standard boron functional groups, such as pinacol
boronic (BPin) esters, cannot undergo.2 Accordingly, synthetic
methods for their preparation are of particular value. Typical
preparations involve monoboron transfer processes including
the use of stoichiometric organometallic reagents, such as an
organolithium or Grignard reagent, with a borate ester and
subsequent hydrolysis,1 or Pd-catalyzed processes that can
directly install the B(OH)2 unit.
3 However, the majority of
catalytic processes using, for example, Co,4 Ir,5 Ni,6 or Pd7
catalysis generate the BPin ester products, which require further
processing to access the parent B(OH)2 motif.
8
Protecting group methods,9−12 such as MIDA boronic esters
(BMIDA),9 have enabled discrimination within diﬀerentiated
diboron systems, allowing chemoselective cross-coupling of a
reactive boronic acid or ester, with a suitable electrophile, to
deliver a new C−C bond while retaining the BMIDA unit
(Scheme 1a). Protecting group removal reveals the latent
boronic acid, which can then be further reacted. Alternatively,
in situ hydrolysis/Suzuki−Miyaura cross-coupling methods of
BMIDA species have been developed.9i,k We have recently
shown that the direct generation of BPin esters can be achieved
by control of the solution speciation during cross-coupling of
monoprotected diboron (BPin/BMIDA) systems (Scheme
1b).13 This directly provides a moderately reactive boronic
ester product and avoids postreaction protecting group
manipulation as well as facilitating the ﬁrst approach to
chemoselective sequential Suzuki−Miyaura cross-coupling
using dielectrophile/dinucleophile systems.14,15 Based on their
increased versatility, direct access to boronic acids via
manipulation of diboron systems during cross-coupling would
be a valuable addition to the chemical toolbox and would
present signiﬁcant opportunities for the development of
multibond forming tandem reactions. Here we show the
development of a formal boronic acid homologation protocol
using B(OH)2/BMIDA diboron systems (Scheme 1c), enabled
by control of the basic phase, and the utility of this process as a
platform for diversity-oriented synthesis in the context of
epigenetic drug discovery.
We ﬁrst examined the formal homologation reaction in a
benchmark process using PhB(OH)2 (1) and 4-bromophe-
nylboronic acid MIDA ester (2), using a catalyst and medium
composition based on our previous work (Table 1, entry
1).13a,b While good conversion to 3a was recorded, signiﬁcant
protodeboronation was observed. Decreasing the reaction time
assisted in moderating this product decomposition pathway but
led to incomplete hydrolysis of intermediate 4 (entry 2).
Increasing H2O loading resolved this problem but again led to
increased protodeboronation as well as oligomerization (entry
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Scheme 1. Suzuki−Miyaura Cross-Coupling with Haloaryl
BMIDA Esters: (a) Retention of BMIDA; (b) Generation of
BPin; (c) Formal Homologation of Boronic Acids
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3). Balancing the H2O/K3PO4 composition mitigated these
issues (entries 4 and 5). Lowering the reaction temperature
(entry 6) and variation of catalyst (entries 7 and 8) were
detrimental. However, decreasing the reaction concentration
was advantageous, providing 90% conversion to the desired
formal homologation adduct with minimal decomposition
(entry 9). These optimized conditions provide a suitable
medium for eﬀective cross-coupling14 while controlling
aqueous base availability to mitigate BMIDA hydrolysis until
after the initial C−C bond formation has reached completion.
With eﬀective conditions in hand, we moved to establish the
generality of the formal homologation process (Scheme 2). The
developed protocol operated eﬀectively across a broad range of
substrates with variation of the boronic acid component as well
as the conjunctive BMIDA unit readily tolerated. The boronic
acid component accepted common functional groups including
alkyl, amine, ether, thioether, halide, and heterocyclic motifs.
Chemoselective cross-coupling was amenable with the
bromoaryl BMIDA substrate undergoing oxidative addition
over less reactive aryl chloride residues (3o). Notably, both
bromovinyl BMIDA and bromoheteroaryl BMIDA components
could be employed to deliver the corresponding vinyl (3b, 3g,
3s) and heteroaryl (4c, 3d, 3i, 3o, 3r) boronic acid products,
respectively. Similar species are known to be prone to
protodeboronation, but these components performed eﬃ-
ciently in the developed process.9g,j
However, we did observe limitations of the process in the use
of heterocyclic 2-boronic acids (benzothiophene, furan,
pyridine, and thiophene) as starting materials as well as
conjunctive haloheterocyclic 2-BMIDA (e.g., 5-bromothio-
phene 2-boronic acid MIDA ester) that would generate
heterocyclic 2-boronic acid products. In these cases, proto-
deboronation was found to be signiﬁcant and the homologation
reaction less eﬀective.
The utility of the formal homologation protocol to provide
rapid access to valuable and novel chemical space was
demonstrated in the context of diversity-oriented synthesis
based on a favored pharmacophore that is currently used within
epigenetic drug discovery. BET bromodomain inhibitors are
targets of particular interest within drug discovery programs.16
Compound 6 is an inhibitor of BRD4 and CREBBP (Scheme
3).17 The key feature of this molecule is the dimethylisoxazole
motif, which acts as an AcK mimic, with the core trisubstituted
arene and pendant phenylmethanol providing isoform
selectivity and potency modulation vectors.17 Installation of
the dimethylisoxazole warhead (7) onto the 1,3,5-trisubstituted
aryl core (8) using the developed boronic acid homologation
protocol provides the key intermediate 3v in 83% yield.





1 PdCl2dppf (5 mol %), K3PO4 (3 equiv), H2O (5 equiv),
0.25 M, 90 °C, 16 h
67:0:33
2 PdCl2dppf (5 mol %), K3PO4 (3 equiv), H2O (5 equiv),
0.25 M, 90 °C, 4 h
70:27:3
3 PdCl2dppf (5 mol %), K3PO4 (3 equiv), H2O (20 equiv),
0.25 M, 90 °C, 4 h
60:0:40
4 PdCl2dppf (5 mol %), K3PO4 (4 equiv), H2O (20 equiv),
0.25 M, 90 °C, 4 h
82:0:18
5 PdCl2dppf (5 mol %), K3PO4 (4 equiv), H2O (7 equiv),
0.25 M, 90 °C, 4 h
84:8:8
6 PdCl2dppf (5 mol %), K3PO4 (4 equiv), H2O (7 equiv),
0.25 M, 80 °C, 4 h
63:1:36
7 Pd(PPh3)4 (5 mol %), K3PO4 (4 equiv), H2O (7 equiv),
0.25 M, 90 °C, 4 h
47:0:53
8 Pd(OAc)2 (5 mol %), SPhos (10 mol %), K3PO4
(4 equiv), H2O (7 equiv), 0.25 M, 90 °C, 4 h
32:2:66
9 PdCl2dppf (5 mol %), K3PO4 (4 equiv), H2O (7 equiv),
0.1 M, 90 °C, 4 h
90:6:4
a1 (1.1 equiv, 0.275 mmol), 2 (1 equiv, 0.25 mmol), Pd catalyst (5
mol %), K3PO4, H2O, THF, N2.
bDetermined by HPLC analysis using
an internal standard.
Scheme 2. Substrate Scope of the Formal Homologation
Reactiona
aIsolated yields of pure products. bIsolated as the BF3K derivative.
Organic Letters Letter
DOI: 10.1021/acs.orglett.5b03030
Org. Lett. 2015, 17, 6030−6033
6031
The versatility of the boronic acid motif can then be
exploited using established chemistries. For example, further
Suzuki−Miyaura reactions using sp2- and sp3-hybridized
electrophiles provided 9a and 9g, respectively in excellent
yield. 9g can be readily converted to the parent compound 6
using existing methods.13 Chan−Evans−Lam coupling pro-
vided the morpholine derivative 9b in 78% yield while Hayashi-
type 1,4-addition eﬃciently delivered 9c in 74% yield.
Straightforward Brown-type oxidation to the phenol 9d
proceeded quantitatively. An oxidative Heck reaction with
methyl acrylate eﬃciently produced 9e and, last, the reactivity
of the boron-bearing carbon could be inverted by bromination
to give 9f. It is important to note that several of these products
(e.g., 9b, 9c, 9f) cannot be so readily achieved with either the
corresponding BMIDA or BPin derivative of 3v;2a,d these
derivatives would require either further processing or
alternative, less straightforward chemistries.
In summary, we have developed a boronic acid formal
homologation reaction using boronic acids and conjunctive
bromoaryl/vinyl BMIDA components. The process relies upon
careful control of the basic biphase to enable cross-coupling of
haloaryl BMIDA components while avoiding premature
hydrolysis. This process gives direct access to functionalized
boronic acids that can be used as a platform for diversity-
oriented synthesis within drug discovery.
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